On Friday, the U.S. District Court for the District of Columbia granted the motion from the U.S. Federal Trade Commission (FTC) for an injunction blocking Edwards Lifesciences Corp’s (NYSE: EW) ...

The FDA has approved Edwards Lifesciences Corp.’s Sapien M3 transcatheter mitral valve replacement system. The U.S. approval, announced last week, comes eight months after the device received CE Mark ...

The following are the top rated Health Care stocks according to Validea's Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that ...

Edwards Lifesciences has persuaded CMS to publish an updated tracking sheet for TAVR national coverage analysis. The move is causing CMS to reconsider its previous stance on covering transcatheter ...

Innovation with Purpose, Powered by Science, Centered on Patients: Edwards’ Commitment to Drive Value for the Healthcare Ecosystem IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (EW) will ...

Edwards Lifesciences (NYSE: EW) will outline its patient-focused strategy and share financial guidance during its annual investor conference. Entering 2026 with momentum for sustainable differentiated ...

While the first innovators in the area of minimally invasive cardiac procedures began introducing methods such as finger-fracture valvuloplasty as early as the 1920s — in the case of England’s Henry ...

Low-risk patients with severe, symptomatic aortic stenosis show similar clinical outcomes and valve durability. HealthDay News — Seven-year follow-up data show that transcatheter aortic-valve ...

Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical ...

Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, outcomes were similar among patients who had undergone transcatheter aortic-valve ...